Indeed, in a phase I clinical trial of 23 patients with Her2+ metastatic BC, eight infusions of polyclonal activated T cells transduced with anti-CD3 and anti-Her2 bispecific antibodies (Her2Bi), termed armed ACT (aACT) [100], successfully induced anti-tumor responses and were safe in patients with visceral metastases [101]. Here, ERBB2 is linked to breast cancer.